通过从耐辐射结直肠癌细胞中获得的基因面板来预测瘤的重新扩散
Yanwei Song1,2, Zheng Deng1,2, Haoran Sun1,2
1Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201620, China.
Journal of translational medicine
|June 16, 2023
概括
抗辐射的瘤细胞驱动了放射治疗后癌症的再生. 使用四个基因 (LGR5,KCNN4,TNS4,CENPH) 的新预后指标可以预测结直肠癌和其他癌症患者的结果.
科学领域:
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
- 遗传学 遗传学 是一个
背景情况:
- 瘤细胞的抗辐射性促进治疗失败和瘤再生.
- 其余的耐药细胞显著降低了后续疗法的疗效,导致临床结果差.
- 了解抗辐射细胞在瘤再生中的作用对于改善癌症患者预后至关重要.
研究的目的:
- 确定与结直肠癌中辐射抵抗相关的关键基因.
- 开发一种预后指标,用于预测放射治疗后患者的结果.
- 调查已识别的基因在瘤放射性敏感性和重组中的作用.
主要方法:
- 利用GEO和TCGA数据集来识别辐射耐药细胞中共同表达的基因.
- 执行单变量和多变量考克斯回归,后勤分析和WGCNA以建立和验证预后指标.
- 采用RT-qPCR和克隆基因测试来评估结直肠癌细胞系中的基因表达,放射性敏感性和重新繁殖能力.
主要成果:
- 一个包括LGR5,KCNN4,TNS4和CENPH的预后指标是为TCGA结肠直肠癌患者开发的.
- 该指标与接受放射治疗的结直肠癌患者的预后有显著的相关性,并在其他五种癌症类型中显示出预测价值.
- 通过RT-qPCR证实基因表达水平与辐射耐药性保持一致,这些基因的淘汰降低了辐射后的克隆基因和重组能力.
结论:
- LGR5,KCNN4,TNS4和CENPH与结直肠癌细胞的辐射敏感性和整体预后有关.
- 开发的预后指标有效地预测了接受放射治疗的患者的结果.
- 这项研究提供了证据,证明耐辐射细胞参与瘤再生,并为放射治疗患者提供了宝贵的预后工具.
相关概念视频
02:07Tumor Progression
6.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K